Each unit of cost invested in Helicobacter pylori screening can generate approximately a fivefold return in gastric cancer prevention benefits.

The gastric cancer prevention research team at National Taiwan University Hospital and College of Public Health, National Taiwan University, has pioneered a globally applicable preventive model for gastric cancer control. To inform public health policymaking, the research team developed a globally adaptable decision-tree model to evaluate the cost-effectiveness of H. pylori screening. The findings were published in JAMA on June 1, 2026.

Building on Taiwan’s nationwide fecal immunochemical test-based colorectal cancer screening program, the gastric cancer prevention team has conducted a 10-year randomized clinical trial demonstrating that the additional use of an H. pylori stool antigen test (HPSA) alongside fecal occult blood testing could simultaneously achieve the dual goals of colorectal cancer and gastric cancer prevention. The findings were previously published on Sept. 30, 2024, in JAMA.